RVX_logo_RGB.jpg
Study Demonstrates Resverlogix’s Apabetalone Treatment Significantly Improves Cognition and Reduces Cognitive Decline Among Patients with Both Cardiovascular Disease and Diabetes Mellitus
September 13, 2021 08:00 ET | Resverlogix Corp
Positive Findings in Journal of Alzheimer's Disease Suggest BET Inhibitor Apabetalone Holds Promise as a Safe and Effective Therapeutic for Vascular Cognitive Impairment Apabetalone is a...
RVX_logo_RGB.jpg
Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study
September 08, 2021 08:00 ET | Resverlogix Corp
Apabetalone, a First-in-Class Epigenetic Therapeutic Candidate, Met Key Endpoint of Lowering Pulmonary Vascular Resistance (PVR) and Was Well Tolerated Successful Completion and Promising Results of...
RVX_logo_RGB.jpg
Resverlogix Announces Management Change
July 06, 2021 06:00 ET | Resverlogix Corp
CALGARY, Alberta, July 06, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced that Ken Lebioda is stepping down as Senior Vice President, Business and Corporate...
RVX_logo_RGB.jpg
Resverlogix Announces Voting Results from the 2021 Meeting of Shareholders
June 23, 2021 00:16 ET | Resverlogix Corp
CALGARY, Alberta, June 22, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual and Special Meeting of Shareholders (the “Meeting”) in...
RVX_logo_RGB.jpg
Resverlogix和EVERSANA宣布合作以支持即将在美国和加拿大启动的Apabetalone初始商业化
June 04, 2021 09:17 ET | Resverlogix Corp
阿尔伯塔省卡尔加里和芝加哥, June 04, 2021 (GLOBE NEWSWIRE) -- Resverlogix...
RVX_logo_RGB.jpg
Resverlogix 與 EVERSANA 宣佈建立合作夥伴關係,以支持用於治療 2019 冠狀病毒病的 apabetalone 在美國和加拿大的初期商業化活動
June 04, 2021 09:17 ET | Resverlogix Corp
亞伯達省卡加利和芝加哥, June 04, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (Resverlogix) (TSX:RVX) 與全球生命科學行業下一代商業服務的先驅 EVERSANA™ 今天宣佈建立合作夥伴關係,以支持 apabetalone 計劃在美國和加拿大(已授權對用於治療 2019 冠狀病毒病的 apabetalone...
RVX_logo_RGB.jpg
Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone for COVID-19 in the United States and Canada
June 03, 2021 08:04 ET | Resverlogix Corp
CALGARY, Alberta and CHICAGO, June 03, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) and EVERSANA™, the pioneer of next generation commercial services to the global life...
RVX_logo_RGB.jpg
Resverlogix Announces US$6 Million Debenture Financing
May 05, 2021 10:01 ET | Resverlogix Corp
CALGARY, Alberta, May 05, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that it has entered into an investment agreement with a subsidiary of...
Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease
April 27, 2021 13:41 ET | Resverlogix Corp
CALGARY, Alberta, April 27, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “Effect of Apabetalone...
RVX_logo_RGB.jpg
Apabetalone’s Positive Impact on COVID-19 in Human Lung Cells Published in Biomedicines
April 20, 2021 08:00 ET | Resverlogix Corp
CALGARY, Alberta, April 20, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today the publishing of an article titled: “Bromodomain and extraterminal protein...